马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析

doi:10.19438/j.cjoms.2017.06.010

摘要/Abstract

摘要： 目的比较外用马来酸噻吗洛尔与口服普萘洛尔治疗婴幼儿表浅型血管瘤的疗效。方法回顾分析中国医科大学附属口腔医院口腔颌面外科门诊收治的50例表浅型血管瘤患儿, 27例外用0.5%马来酸噻吗洛尔滴眼液,为A组;23例采用口服普萘洛尔治疗,为B组。随访12个月,每个月定期复诊。采用SPSS18.0软件包对数据进行秩和检验,比较2组治疗效果、显效时间及不良反应的差异。结果随访12个月,A组显效率为63.0%, B组显效率为65.2%,2组治疗效果及显效时间无显著差异（P>0.05）;A组不良反应显著少于B组（P<0.05）,2组均未出现危及患儿生命的严重不良反应。结论采用外用马来酸噻吗洛尔治疗婴幼儿表浅型血管瘤安全有效。与口服用药相比, 本方法效果显著且不良反应少,可推荐为一线用药方案。

关键词: 婴幼儿血管瘤, 马来酸噻吗洛尔, 普萘洛尔

Abstract: PURPOSE: To investigate the clinical effects of 0.5% timolol maleate solution or oral propranolol in treating superficial infantile hemangiomas. METHODS: A total of 50 patients with superficial infantile hemangiomas were retrospectively analyzed, 27 cases received topical 0.5% timolol maleate solution alone (group A), and 23 cases received oral propranolol alone (group B). Patients were followed up for 12 months. SPSS18.0 software package was used to compare the difference of therapeutic efficacy, the response time and adverse reactions between group A and group B. RESULTS: The effectiveness of group A and group B was 63.0%and 65.2%, respectively. The therapeutic efficacy and response time after 12 months had no significant difference between group A and B (P>0.05). Compared with group B, group A had fewer adverse reactions（P<0.05）. No serious adverse effects were encountered in both groups. CONCLUSIONS: Topical 0.5% timolol maleate solution is effective and safe in the treatment of superficial infantile hemangiomas. It could be considered as the first-line treatment especially for superficial infantile hemangiomas.

Key words: Infantile hemangiomas, Timolol maleate, Propranolol

中图分类号:

R739.8

张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.

ZHANG Kai-chi, XU Da-peng, CHENG Mo-sha, WANG Xu-kai. Evaluation of the efficacy and safety of 0.5% timolol maleate solution or oral propranolol in the treatment of superficial infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2017, 15(6): 529-533.

参考文献

[1] Liekens S, Verbeken E, Vandeputte M, et al. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470[J]. Cancer Res, 1999, 59(10): 2376-2383.
[2] Bruckner AL, Frieden IJ. Hemangiomas of infancy[J]. J Am Acad Dermatol, 2003, 48(4): 477-493.
[3] Phung TL, Hochman M, Mihm MC. Current knowledge of the pathogenesis of infantile hemangiomas [J]. Arch Facial Plast Surg, 2006, 7(5): 319-321.
[4] Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development[J]. Pediatrics, 2006, 117(3): 698-703.
[5] 王绪凯. 脉管性疾病的治疗 [J]. 中国实用口腔科杂志, 2009, 2(5): 280-282.
[6] 刘宇楠, 刘宇. 婴幼儿腮腺区血管瘤治疗的研究进展 [J]. 国际口腔医学杂志, 2012, 39(4): 487-490.
[7] 王绪凯, 谭海松, 秦兴军. 血管瘤及血管畸形治疗方法的选择[J]. 口腔颌面外科杂志, 2012, 22(3): 153-156.
[8] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[9] Zheng JW. Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma[J]. Cutan Ocul Toxicol, 2011, 30(4): 333-334.
[10] 靳职雷, 续艳玲, 薛雷, 等. 口服普萘洛尔治疗婴幼儿增生期血管瘤35例临床分析[J]. 中国口腔颌面外科杂志, 2012, 10(2): 159-162.
[11] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatrics, 2013, 131(1): 128-140.
[12] Sagi L, Zvulunov A, Lapidoth M, et al. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases [J]. Dermatology, 2014, 228(2): 136-144.
[13] 孙桦梁, 刘晓红, 席善龙, 等. 口服普萘洛尔治疗婴幼儿腮腺区血管瘤的疗效观察[J]. 口腔颌面外科杂志, 2013, 23(6): 463-466.
[14] Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using β-blocker solution [J]. Arch Ophthalmol, 2010, 128(2): 255-256.
[15] Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics [J]. J Pediatr, 2007, 150(3): 291-294.
[16] Maguiness SM, Frieden IJ. Current management of infantile hemangiomas [J]. Semin Cutan Med Surg, 2010, 29(2): 106-114.
[17] 郑家伟. 婴幼儿血管瘤"等待观察"的治疗策略应予改变 [J]. 中国口腔颌面外科杂志, 2012, 10(2): 163-164.
[18] Cohen-Barak E, Rozenman D, Shani Adir A. Infantile haemangiomas and quality of life[J]. Arch Dis Child, 2013, 98(9): 676-679.
[19] Boon LM, Macdonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma [J]. Plast Reconstr Surg, 1999, 104(6): 1616-1623.
[20] Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases [J]. J Pediatr Surg, 2000, 35(3): 420-423.
[21] Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years' experience of steroids in infantile hemangioma a developing country's perspective [J]. J Pediatr Surg, 2009, 44(4): 688-694.
[22] Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors [J]. Pediatr Dermatol, 2011, 28(6): 663-669.
[23] Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas [J]. Eur J Pediatr, 2011, 170(4): 493-501.
[24] de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants[J]. J Am Acad Dermatol, 2011, 65(2): 320-327.
[25] Blatt J, Morrell DS, Buck S, et al. β-blockers for infantile hemangiomas: a single-institution experience[J]. Clin Pediatr (Phila), 2011, 50(8): 757-763.
[26] Shah S, Frieden IJ. Treatment of infantile hemangiomas with β-blockers: a review [J]. Skin Therapy Lett, 2013, 18(6): 5-7.
[27] Hao J, Yang MB, Liu H, et al. Distribution of propranolol in periocular tissues: a comparison of topical and systemic administration [J]. J Ocul Pharmacol Ther, 2011, 27(5): 453-459.
[28] Volotinen M, Hakkola J, Pelkonen O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug [J]. Basic Clin Pharmacol Toxicol, 2011, 108(5): 297-303.
[29] Chu MB, Searcy G, Siegfried E. Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing [J]. Bmj Case Rep, 2013, pii: bcr2013009365.
[30] 宫贺, 徐大朋, 李越霄, 等. 0.5%马来酸噻吗洛尔滴眼液联合普萘洛尔治疗婴幼儿血管瘤疗效分析 [J]. 中国口腔颌面外科杂志, 2014, 12(5): 441-445.
[31] Xu DP, Cao RY, Tong S, et al. Topical timolol maleate for superficial infantile hemangiomas: an observational study [J]. J Oral Maxillofac Surg, 2015, 73(6): 1089-1094.
[32] Xu DP, Cao RY, Xue L, et al. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients [J]. J Oral Maxillofac Surg, 2014, 73(3): 430-436.
[33] Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome [J]. Brit J Dermatol, 2011, 164(4): 886-888.
[35] Cante V, Phamledard A, Imbert E, et al. First report of topical timolol treatment in primarily ulcerated perineal haemangioma [J]. Arch Dis Child Fetal Neonatal Ed, 2012, 97(2): F155-156.
[35] Thomas J, Kumar P, Kumar DD. Ulcerated infantile haemangioma of buttock successfully treated with topical timolol[J]. J Cutan Aesthet Surg, 2013, 6(3): 168-169.
[36] 郑家伟. 外用马来酸噻吗洛尔治疗婴幼儿血管瘤中国专家共识 [J]. 上海口腔医学, 2016, 25(6): 744-747.